Columbia Labs' Prochieve Could Address $150 Million To $300 Million Preterm Birth Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm anticipates sNDA approval for progesterone vaginal gel product in recurrent preterm birth as early as 2008.